Recent Updates in Psychopharmacology for the Core and Associated Symptoms of Autism Spectrum Disorder

Key Findings:  Early studies on the use of cannabidiol (CBD) to reduce irritability in patients with autism spectrum disorder (ASD) have failed to show safety or efficacy. More research is needed.

Type of Study:  Meta-analysis

Study Result:  Inconclusive

Study Location(s):  United States

Year of Pub:  2021

Cannabinoids Studied:  Cannabidiol (CBD)

Phytocannabinoid Source:  Not Applicable

Chemotype:  Chemotype III

Ligands Studied:  Oxytocin, Serotonin, Vasopressin